EsoCap AG has been featured in Fierce Pharma Online. “We are extremely pleased that Fierce Pharma Online reviewed EsoCap’s unique and innovative topical drug delivery system to the esophagus and…

EsoCap AG has received Orphan Drug Designation from the United States Food & Drug Administration (FDA) for use of ESO-101 in the treatment of EoE (eosinophilic esophagitis). “We are pleased…

EsoCap AG organized a multidisciplinary scientific advisory board meeting in Zurich with thirteen international experts on June 27, 2019. As an introduction, Prof. Werner Weitschies, Center for Drug Absorption and…

EsoCap AG announced that a capital increase has been authorized by the Extraordinary General Assembly, held on April 11, 2019, followed by successful completion of a private placement financing. The…

Basel, Switzerland, February 6, 2019 EsoCap AG and LTS Lohmann Therapy-Systeme AG announced the start of cooperation on industrial development of a unique drug delivery technology for diseases of the…

Basel, Switzerland, July 13th, 2018 EsoCap AG announced that it has successfully completed a private placement financing round on July 13th, 2018. The proceeds of the capital increase will be…

EsoCap AG organized a scientific advisory board meeting with eight international experts in Eosinophilic Esophagitis (EoE) in Zürich on June 14th, 2018. Prof. Dr. Werner Weitschies, Head of the Center of Drug Absorption and Transport at the University of Greifswald gave a keynote presentation on EsoCap’s unique drug delivery platform.

EsoCap AG announced today that the South Africa Patent and Trademark Office has issued the Patent No.  2017/03831 on March 28th, 2018 which is directed at the smart application technology enabling specific site-directed treatments of several diseases of the esophagus.

EsoCap announced that Sven Hoffmann and Isabelle Racamier have been appointed to the Company’s Board of Directors. “I am delighted to welcome Isabelle and Sven to the EsoCap Board. Both…